Log In
Print
BCIQ
Print
Print this Print this
 

Zalviso (ARX-01) (formerly Sufentanil NanoTab PCA System)

Also known as: Sublingual Sufentanil NanoTabs

  Manage Alerts
Collapse Summary General Information
Company AcelRx Pharmaceuticals Inc.
DescriptionPre-programmed, handheld device that delivers a sublingual formulation of sufentanil, a synthetic opioid analgesic
Molecular Target Opioid receptor (OPR)
Mechanism of ActionOpioid receptor agonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentRegistration
Standard IndicationPain
Indication DetailsManage postoperative pain in patients undergoing unilateral knee replacement surgery; Treat moderate to severe acute pain following knee replacement surgery; Treat moderate to severe acute pain in a hospital setting; Treat postoperative pain following major surgery; Treat postoperative pain following total unilateral knee or hip replacement surgery; Treat postoperative pain in patients undergoing major abdominal surgery
Regulatory Designation

Partner

Gruenenthal Group


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$250.0M

$30.0M

$220.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today